Molecular perspective on targeted therapy in breast cancer: a review of current status

Trastuzumab and pertuzumab inhibit HER2 signaling by binding to the extracellular domain of HER2. Lapatinib, neratinib, tucatinib, and pyrotinib inhibit HER signaling by binding to the intracellular tyrosine kinase domain of the Her family members. EGFR epidermal growth factor receptor, HER human epidermal growth factor receptor, MEK MAP kinase kinase, ERK MAP kinase, PI3K phosphoinositide 3-kinases (adapted from “HER2 Signaling Pathway”, by BioRender.com (2022). Retrieved from https://app.biorender.com/biorender-templates)

Publication

Molecular perspective on targeted therapy in breast cancer: a review of current status. (2022) Busra Demir Cetinkaya, et al. Med Oncol. 2022;39(10):149. Figure: F1. All organisms Homo sapiens Drosophila melanogaster

Disease mentions